A message from TrialNet Chair Carla Greenbaum, M.D.

At TrialNet, the health and safety of our participants and research teams is always our top priority.

With landmark results recently announced, the Teplizumab Prevention Study is making headlines across the country. Here, Tracy Olsten shares why her daughter Mikayla decided to join the study.

Teplizumab Prevention Study Chair Kevan Herold, M.D., Yale University, presented first-of-a-kind findings showing that teplizumab delayed type 1 diabetes a median of 2 years in children and adults at high risk. Findings were also simultaneously published in the New England Journal of Medicine